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µWe all have a responsibility to each other¶: valuing racialised bodies in the 
neoliberal bioeconomy 
 
Sibille Merz & Rosalind Williams 
 
 
Abstract 
In neoliberalism, human tissue has been targeted as a novel source for the extraction of 
surplus value. Entire new markets for human biomaterials such as reproductive tissue, organs 
and clinical data have emerged. Commercial attention has also turned to ethnic and racial 
minorities, resulting in myriad products and services specifically developed for them. In this 
paper, we focus on this market interest in racialised tissue by exploring two contested 
empirical examples: clinical trials for pharmaceuticals in the United States and stem cell 
transplantation in the United Kingdom. Both examples use racial taxonomies as useful tools 
in discerning human biological difference to draw conclusions about the economic potential 
of donorV¶DQGSDUWLFLSDQWV¶ genetic constitutions. We will show, first, how they do so by 
DSSHDOLQJWRUDFLDOLVHGPLQRULWLHV¶VHQVHRIresponsibility toward µtheir¶ communities, not 
only actively buttressing the conflation of the social and biological registers of human 
variation but also demonstrating QHROLEHUDOLVP¶VPRELOLVDWLRQRIdiscourses of community. 
However, while the inclusion of racialised minorities is hoped to bring economic benefits, it 
also aims to work towards the beneficent ends of addressing racial inequalities in healthcare 
provision. Drawing on debates in Science and Technology Studies, we argue, second, that in 
our examples, economic, social and cultural values cannot be disentangled. This compels us 
to complement narratives of the commodification of racialised difference in neoliberal 
(consumer) culture, and focus on the intersections between different values pertaining 
simultaneously to economic and ethical realms. Ultimately though, we find that whilst 
important work is being done to ameliorate racial inequities, the broader socio-economic and 
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political inequalities minority communities face go unaddressed, likely precluding the 
UHDOLVDWLRQRIELRVFLHQFH¶VSURPLVHRIKHDOWKHTXDOLW\ 
Keywords: race; neoliberalism; science and technology studies; clinical trials; stem cell 
donation 
 
Introduction 
Over the past three decades or so, new biomedical technologies have, through licensing 
agreements, patenting, and innovation monopolies, become the basis for a plethora of 
lucrative investments. From the development of powerful immunosuppressants that 
revolutionised transplant medicine, to sophisticated assisted reproductive technologies, 
fundamentally transforming our understanding of human reproduction, it is increasingly the 
molecular qualities and regenerative capabilities of the human body that are being put into the 
service of both bioscientific endeavours and commercial exploitation (Cooper, 2008; Cooper 
and Waldby, 2014; Lock, 2001; Rose, 2006; Scheper-Hughes, 2001).  
Such scientific practices have also re-established the discussion of meaningful human 
differences along racial lines. Though race has, since the horrors of World War II and Nazi 
science, been discredited as a biological category and shown to lack any scientific credibility 
(but Reardon, 2005), entire new industries have been built around the idea that the category 
can be determined at the minuscule level of DNA. From genetic ancestry testing (Nelson, 
2008; Bolnick et al. 2007) to race-specific medicine (Kahn, 2012; Roberts, 2010; Inda, 2014) 
we can find numerous examples of how science produces opportunities to make racial 
difference economically valuable. ,QOLQHZLWKQHROLEHUDOLVP¶VFUHDWLRQRIQHZUDFLDOLVHG
markets ± advertising, cars or sports clothing are only a few examples (Whitmarsh and Jones, 
2010) ± the mutually constitutive practices of the life sciences and the tenets of market 
stratification and product differentiation have also produced novel markets in racialised 
human tissue.  
In this context, this paper examines two empirical examples, clinical drug trials in the United 
States and umbilical cord blood stem cell banking in the United Kingdom, that centre on the 
enrolment of racial and ethnic minorities, aiming to generate economic benefits from 
racialised tissue. Emerging out of larger research projects in which we have each investigated 
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specific aspects of the complex entanglements of race, bioscience and the creation of new 
markets ± the relations between research on human diversity and the globalisation of clinical 
WULDOV$XWKRU¶VQDPHUHPRYHGDQGWKHSURFHVVHVRIHQFRXUDJLQJSRWHQWLDOPLQRULW\HWKQLFLW\
donors to participate in umbilicaOFRUGEORRGEDQNLQJLQ8.VWHPFHOOJRYHUQDQFH$XWKRU¶V
name removed) ± we empirically investigate how, DV3DXO*LOUR\SXWVLW³>Q@HROLEHUDOFXOWXUH
DQGHFRQRPLFKDELWVXQHDUWKHGWKHYDOXHLQSUHYLRXVO\DEMHFWHGEODFNOLIH´*LOUR\
In neoliberal consumer culture, racial difference RUµGLYHUVLW\¶has undergone a valuating 
process, shifting representations of race associated with crime or poverty to making it the 
locus of µpositive¶ markers such as uniqueness, creativity, and rarity. Bioscientific products 
VXFKDV%L'LOWKHZRUOG¶VILUVWVR-called ethnic drug (Kahn, 2012), or personal genomics 
FRPSDQ\DQG0H¶V$IULFDQ$QFHVWU\3URMHFW0HU]are expressions of such a new 
valuing of racial difference, not least for its commercial appeals. 
However, in this paper we seek to problematise the assumption that such markets are merely 
another expression of the commodification of racial difference, or an extension of the 
historical extraction of surplus value from racialised bodies to racialised cells. Though authors 
such as Dorothy Roberts (2011) aptly emphasise the enduring entanglements of race, 
commerce and conquest since the era of enslavement and colonial violence, we suggest that 
the economic attractiveness of racialised tissue can only be understood in relation to the 
various contemporary social, moral and cultural systems of meaning-making that co-produce, 
and sometimes contradict, it. Important historical, institutional, cultural differences between 
our two cases aside, this value cannot be understood purely in terms of the commodification 
of racialised lives but enfolds economic, ethical and vital value in that money might be made 
(through private drug trials) or saved (through public stem cell banks) but lives also 
lengthened or improved, and historical wrongs addressed (Dussauge et al., 2015). What 
1LNRODV5RVHKDVFDOOHGWKH³ELRORJ\RIWKHSUHVHQW´FDQQRWEHFRPSUHKHQVLYHO\
understood within the trajectory of nineteenth century race science or as merely the latest 
expression of the biogenetic legitimation of social health disparities. Rather, it is part of the 
ODUJHU³HFRQRP\RIKRSH´5RVHWKDWFKDUDFWHULVHVFRQWHPSRUDU\ELRPHGLFDO
practices. We suggest that though problematically reifying and mobilising racialised 
difference as biological by phenotypically matching individuals with their presumed 
communities, present-day bioscientific practices disrupt tidy accounts of economic 
exploitation. We therefore argue for a more nuanced account that acknowledges that practices 
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which operate within market principles to enrol racialised life also portend beneficent health 
outcomes and aim to address historical exclusions. 
Whether or not these efforts will result in actual improvements in health remains highly 
uncertain of course. The health inequalities often pitched as the focus of scientific effort are 
but part of a broader tapestry of socio-economic and political inequalities. These preclude the 
realisation of bioVFLHQFH¶VORIW\SURPLVHVWRLPSURYHKHDOWKHTXLW\DQGSURPSWDEURDGHU
question that needs to be asked about when and why certain lives do, or do not, come to 
matter. We conclude by suggesting that our vignettes propose technological fixes that are 
likely to leave unaddressed the much larger social and economic problems reproducing racial 
health disparities. 
Neoliberal bioscience and the valorisation of vitality 
Neoliberalism, understood here as both a set of governing practices and distinct economic 
policies characterised by a preference to marketplace mechanisms, trade liberalisation and the 
individualisation of risk and responsibility (Moore et al., 2009), has had a concrete impact on 
bioscientific practices in the US and UK. This is evident through the privatisation of 
biotechnology, the commercialisation of life processes and the establishment of rigorous 
patent laws to secure intellectual property (Lave et al., 2010; Moore et al., 2009). The growth 
of post-Fordist modes of production, at least in the Global North, saw a rise in innovation-
driven models of growth in which bioscientific discoveries took centre stage. In the US, 
Reagan-era science policy incorporated massive cutbacks in government services, most 
notably public health, and witnessed large-scale public investments in new technologies as 
well as their commercialisation (Cooper, 2008). The Bayh-Dole Act of 1980, for instance, 
facilitated university ownership of intellectual property; more and more universities began to 
hold patents and cooperate with private companies to develop new products based on their 
findings. IQWKH8.7KDWFKHU¶VPDUNHW-driven ideologies meant a 25% cut in project grants, 
and the value of scientific research was increasingly measured by its potentials for 
commercialisation and profit maximisation (Noble, 2013). The tenets of neoliberalisation 
deeply permeated scientific practice, increasingly determining how research targets were 
defined, where research was conducted and who was to benefit from its results (Loeppky, 
2004). 
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Not merely coinciding with the advent of neoliberalism as a politico-economic project, 
discussions in Science and Technology Studies have argued that the development of the 
contemporary biosciences and neoliberal political economy are mutually constitutive. 
Melinda Cooper, for instance, notes that neoliberalism and the biosciences stand in a 
productive dialogue with each other, reworking the relation between life and debt and pushing 
the boundaries of both economic and biological productivity (2008: 10). )ROORZLQJ)RXFDXOW¶V
assertion that the development of the modern life sciences and classical political economy 
need to be understood as intrinsically entangled phenomena, she demonstrates how the realms 
of biological (re)production and capital accumulation have jointly evolved. Cooper points to 
WKHZD\VLQZKLFKWKHELRWHFKUHYROXWLRQKDVHPHUJHGRXWRIDVHULHVRI³OHJLVlative and 
regulatory measures designed to relocate economic production at the genetic, microbial and 
FHOOXODUOHYHO´ Commercial processes have firmly expanded into the sphere of 
what Rose similarly FDOOV³OLIHLWVHOI´WKHLQFUHDVLQJFRQFHUQZLWK³our growing capacities to 
control, manage, engineer, reshape, and modulate the very vital capacities of human beings as 
OLYLQJFUHDWXUHV´ (2006: 7). 1 In other words, the lab and the factory have become intrinsically 
interlinked; today, companies do not simply apply or market novel scientific findings but are 
themselves at the forefront of innovative research in the life sciences and beyond.  
These entanglements illustrate how the molecular scales of the body have been opened up for 
scientific scrutiny as well as capital accumulation. The oocyte, the stem cell and the microbe 
have become the raw material of the capitalist prodXFWLRQRIYDOXHRULQGHHGRI³biovalue´, 
defined as the ³yield of vitality produced by the biotechnical reformulation of living 
SURFHVVHV´ (Waldby, 2002: 310). More broadly, biovalue refers to the ways in which vitality 
has become a potential source of value, extracted from the very vital and self-reproducing 
properties of human life. As Catherine Waldby (2002) argues, there are two incentives for the 
creation of biovalue. The public incentive is motivated by the hope that new technologies will 
unearth some kind of viable contribution to health, or use value, from human tissues. The 
vitality of the stem cell, for instance, is charged with lessening debility and the improvement 
of overall well-being (ibid.). The second, commercial incentive, aims at the creation of 
                                                          
 
1
 Of course, we must not overemphasise the novelty of these phenomena. The very development of capitalism has 
been premised on the insertion of life (human, animal, plant) into the capitalist mode of production, and the 
DGMXVWPHQW RI ³WKH SKHQRPHQD RI SRSXODWLRQ WR HFRQRPLF SURFHVVHV³ )RXFDXOW 1998: 140-1), but due to the 
limited scope of this paper, we cannot address the question of whether biocapitalism is truly a novel phenomenon 
or an intensification of existing processes of accumulation. 
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exchange value from human materials, producing biological commodities that can be bought 
and sold. Profitable drugs and medical devices are only one example illustrating the bind of 
scientific knowledge creation and its commercialisation. 
Ironically, the focus on the molecular qualities of the human body, alongside its commercial 
appeals, has also reinvigorated the idea that human biological difference can be defined along 
racial lines. Despite the findings of the Human Genome Project that human beings share 
99.9% of their genetic code with one another, the 0.1% that distinguish us have rapidly been 
translated into human variation that neatly maps onto what have previously been understood 
DVUDFHV'HVSLWH*LOUR\¶VKRSHWKDWthough ³GHQRPLFVPD\VHQGRXWWKHVLJQDOWRUHLI\µUDFH¶
as code and information, [but] there is a sense in which it also points unintentionally towards 
µUDFH¶V¶RYHUFRPLQJ´*LOUR\UDFHKDVEHHQILUPO\UH-established as a meaningful 
marker of human variation (Fullwiley, 2007; Roberts, 2010; Whitmarsh and Jones, 2010). 
This interest in racial difference at the level of DNA cannot, of course, be attributed to the 
racialist assumptions of bioscientific research alone but must be located on a complex grid of 
scientific, economic and political objectives. The use of social groupings to define sample 
populations mandated by policy and often stemming from genuine concern over racialised 
health disparities by both politics and activism; the incentives generated by the patent system; 
and the commercial appeals of racialised niche-markets, as we will explore, have all 
significantly contributed to the re-establishment of racial classifications in the life sciences. 
7KURXJKDFRQVWDQW³EDFNDQGIRUWKEHWZHHQSK\VLFDOZRUOGUHIHUHQWVDQGVRFLDOVWUXFWXUH´DV
American sociologist Duana Fullwiley (2007: 8) puts it, race has been reified as an organising 
principle not only of society, but also of nature. Today, bioscientific practices of recruitment, 
storage, organisation and reporting, as Fullwiley argues, firmly rely on population diffences 
described as racial. 
Reaffirmed as existing at the molecular level and moulded with social and political concerns, 
race has therefore also opened up myriad possibilities for commercialisation. The well-
UHKHDUVHGVWRU\RIWKHPDNLQJRI%L'LOWKHZRUOG¶VILUVWVR-called ethnic drug (Inda, 2014; 
Kahn, 2012; Pollock, 2012; Roberts, 2011), is an indicative but not isolated example. Overall, 
26 drugs approved by the US Food and Drug Administration (FDA) between 2008 and 2013 
report potential ethnic and racial difference in the labelling (Ramamoorthy et al., 2015). 
Genetics company Myriad Genetics has modified its patent related to the testing of mutations 
of the breast cancer gene BRCA2 specifically to Ashkenazi Jewish women (Abbott, 2005). In 
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the realm of stem cell science, as we will show, public stem cell banks are increasingly 
looking to recruit ethnic and racial minorities to improve their chances for a suitable match, 
but also to realise economic benefits. In short, not only do new biotechnologies read race at 
the minuscule level of DNA, but the very vitality of racial minorities has become a potential 
source of biovalue, fuelled by both the hope for actual improvements in racial health 
disparities and the incentive of creating exchange value out of racialised tissue. 
Racialised bioscience: Drug trials and stem cells 
In the remainder of the paper, we demonstrate how, in our two empirical vignettes of the 
clinical drug trial and the public stem cell inventory, bioscientists and recruitment agencies 
shuttle between social identities and biolRJLFDOSURFHVVHVE\DSSHDOLQJWRIXWXUHSDUWLFLSDQWV¶
DQGGRQRUV¶VHQVHRIUHVSRQVLELOLW\IRUWKHLUUHVSHFWLYHFRPPXQLWLHV in the hope for tangible 
economic benefits. However, we also argue that the value located in racialised tissue cannot 
be measured in economic terms alone but is equally driven, as Waldby puts it, by the wish for 
DQ³LPSURYHPHQWLQIXQFWLRQLQJDQGZHOO-EHLQJ´. Whether or not the bioscientific 
practices we discuss are suited to meet this aim remains, of course, highly contested.  
To situate this discussion, the following section briefly introduces our two vignettes to 
provide some context to these bioscientific projects. Both are taken from our respective PhD 
projects in which have, in our own ways, explored different aspects of racialised biocientific 
SUDFWLFHV$XWKRU¶VQDPHUHPRYHG has, in her qualitative study of the convergence of 
postgenomic bioscience and clinical trial outsourcing, interviewed 42 scientific experts and 
policy makers working for multinational pharmaceutical companies, Contract Research 
Organisations (CROs) and regulatory authorities across Switzerland, the UK, India, Australia, 
Singapore, Hong Kong and the US. In addition, she has consulted a variety of published and 
unpublished materials such as company reports, proceedings of scholarly conferences, 
interviews with key actors in popular magazines and scientific journals as well as media 
representations such as the ,¶PLQ campaign analysed in this paper. $XWKRU¶VQDPHUHPRYHG) 
research included analysis of key public-domain material produced by national and 
international charities and non-profit organisations, including UK charities involved in 
encouraging minority ethinicity stem cell donation. Other outputs from WKH8.¶V'HSDUWPHQW
RI+HDOWKDQGWKH8.¶VSDUOLDPHQWDU\$OO-Party Parliamentary Group on Stem Cell 
Transplantation were also analysed. The All-Party Parliamentary Group was used to locate 19 
interviewees for qualitative interviews with those involved in the production of policy relating 
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WRWKH8.¶VSXEOLFVWHPFHOO collection arrangement. These individuals included stem cell 
banking personnel, recruitment and collection personnel, clinical professionals, health 
activists and policy-makers. In the case of both projects, most interviews were recorded and 
transcribed, and all materials were coded and memoed using the qualitative data analysis 
software NVivo. 
 
The Clinical Drug Trial in the USA 
The concern over ethnic and racial variability in drug research, understood as both intrinsic 
(genetic) and extrinsic (socio-cultural, environmental) differences, has resulted in what Steven 
Epstein (2007) KDVFDOOHGDQ³LQFOXVion-and-GLIIHUHQFHSDUDGLJP´, the simultaneous inclusion 
of minorities and their reproduction as biologically distinct. While there is no coherent 
definition of the terms racial and ethnic ± races tend to be defined as sharing biogenetic 
characteristics or geographical origins, and ethnicity usually refers to a social group with 
shared cultural values and lifestyle patterns (Ramamoorthy et al., 2015) ± this new approach 
LQVFLHQFHSROLF\DLPVDW³WKHLQFOXVLRQRIPHPEHUVRIvarious groups generally considered to 
have been underrepresented previously as subjects in clinical studies; and the measurement, 
within those studies, of differences (by sex, race, ethnicity, and age) with regard to treatment 
effects, disease progressionRUELRORJLFDOSURFHVVHV´(Epstein, 2008).  
The growing awareness of ethnic and racial differences culminated in the National Institutes 
of Health (NIH) Revitalization Act in 1993, a piece of legislation that made the inclusion of 
women and ethnic minorities mandatory for all NIH-funded studies. The Act sought to ensure 
that clinical trials were designed in a way that allowed separate analyses of whether the 
variables under study affected women and ethnic or racial minorities differently than the 
hitherto largely white, male, middleclass and heterosexual body as the standard of biomedical 
research (for a more comprehensive genealogy of the Act, see Epstein, 2007). As critics of the 
new policy, and of the renewed focus on race more generally, have warned, conflating 
bureaucratic and scientific categories of difference has given race new salience as a biological 
rather than a social unit of analysisSRWHQWLDOO\RSHQLQJXSDUHWXUQRIHXJHQLFVµWKURXJKWKH
EDFNGRRU¶ (Duster, 2006; also Bliss, 2012; Epstein, 2007; Fullwiley, 2007; Roberts, 2011).                                                                                                                
Over two decades after the Act, the recruitment of racial and ethnic minorities into clinical 
trials has remained a central focus of state-sponsored biomedical research and regulatory 
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approval. A recent study by researchers at the University of California at Davis found that 
racial and ethnic minorities constitute less than 5% of trial participants, with less than 2% of 
cancer research focusing on cancer subtypes disproportionately affecting minorities (Moon et 
al., 2014). A leading NIH expert on inclusion policies interviewed for this research confirmed 
WKDWWKHUHLV³DNLQGRIUH-HPHUJHQFHRIWKDW>WKH5HYLWDOL]DWLRQ$FW@«ZH¶YHEHHQXQGHUDORW
of effort over the past year or two to enhance the rigour and reproducibility of NIH results and 
NIH research. And one piece of that has relevant biological variables like sex or age or other 
IDFWRUV>OLNHUDFHDQGHWKQLFLW\@´LQWHUYLHZZLWKWKHDXWKRU'HVSLWHFRQFHUWHGHIIRUWVWR
improve minority representation, she admitted, these have so far failed to achieve their 
objective of a more equitable distribution of the burdens and benefits of clinical research.  
Responding to such enduring inequalities in biomedical research participation, the US 
Pharmaceutical Research and Manufacturers of America (PhRMA), representing the 
FRXQWU\¶VOHDGLQJUHVHDUFK-based pharmaceutical companies, has joined forces with the 
National Minority Quality Forum (NMQF), an educational organisation dedicated to 
improving health care for racial and ethnic minority populations, to encourage minority 
participation in clinical trials. In 2014, they launched their campaign titled ,¶PLQ, 
consolidating existing efforts to increase diversity by individual companies and charities, and 
SXVKIRUJUHDWHUDZDUHQHVVRIFOLQLFDOWULDOVDVWRPRUURZ¶VPHGLFLQHV7KHFDPSDLJQDLPVDW
reaching African American, Asian American and Hispanic communities which, according to 
latest estimates, make up only 5%, 1-2% and 1% of all clinical trial participants despite 
representing 12%, 5% and 16% of the overall population respectively (PhRMA, 2014; for a 
critical discussion of the well-founded refusal to participate in studies see Benjamin, 2016).  
7KHFDPSDLJQ¶VVKRUWUHFUXLWPHQWYLGHRVKRZVD\RXQJPDOH$IULFDQ$PHULFDQUXQQHU
jogging on a tree-lined and picturesque country road. A male voice-over narrates as lines of 
text fade in, detailing differential health risks for minorities and their marginal involvement in 
clinical trials. As the camera tracks the runner, the narrator describes how biomedical science 
is actively researching innovative medicines to solve these disparities through clinical trials. 
Suddenly though the runner begins to slow, his once effortless gait now appears laboured, and 
he is overtaken by another runner. The camera zooms in with a close-up on thHDFWRU¶VIDFH
and the narrator returns to inform us that something is missing from this life saving project: 
³\RX´$JURXSRIRWKHUUDFLDOO\GLYHUVHMRJJHUVEHJLQRYHUWDNLQJKLPZLWKHDFKSDVVLQJDQG
racially marked jogger, an accompanying text offers more information about that specific at-
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risk population the jogger supposedly represents. For example, as a young Asian woman 
VWHDGLO\MRJVSDVWZHOHDUQWKDW³RQO\RIFDQFHUFOLQLFDOWULDOSDUWLFLSDQWVDUH$VLDQ
$PHULFDQ´8OWLPDWHO\ though, the runner rediscovers his stride and, smiling 
SURXGO\WULXPSKDQWO\OHDGVWKHJURXSZKLOHWKHFDPSDLJQ¶VVORJDQ,¶PLQappears.    
The video, akin to the campaign as a whole, directly links identity politics and phenotypic 
representations with differential disease risks and genetic constitutions, as discussed earlier. 
Racial and ethnic identification are presented as constituting different biological properties 
that signal heightened susceptibility for a specific disease or adverse drug reaction. As other 
critics have warned, by rendering scientific and bureaucratic categories of difference 
functionally equivalent, racial and ethnic categories are firmly re-established as meaningful 
markers of human variation at the level of DNA.  
Drawing on such geneticised understandings of racial groupings, specific Contract Research 
Organisations (CROs) have specialised in the recruitment of racial and ethnic minorities. 
Private firms VXFKDV%ULGJH&OLQLFDO5HVHDUFKEUDQGWKHPVHOYHVDV³WKHSUHPLHUFOLQLFDO
researFKRUJDQL]DWLRQGHGLFDWHGWRSURYLGLQJDOO\RXUGLYHUVLW\UHVHDUFKQHHGV´2, or promise to 
³HQGKHDOWKGLVSDULW\IRU/DWLQRV$IULFDQ$PHULFDQVDQGZRPHQLQWKH86$´3. A distinctive 
UHJLPHRIDV(SVWHLQKDVFDOOHGLW³UHFUXLWPHQWRORJ\´UH-emerges as an auxiliary science 
ZKLFK³evaluates the efficacy of techniques necessary to get bodies into a trial in the first 
place, and to keep them there throughout the life of the H[SHULPHQW´(SVWHLQ
Ironically, demands for greater equity and representation codified in the Revitalization Act 
have also made the hunt for racialised bodies into a lucrative industry. A pharmaceutical 
executive at a multinational drug company interviewed for this research QRWHVWKDW³WKH)'$
tells me in my previous clinical trLDO,GLGQ¶WKDYHDGHTXDWHUHSUHVHQWDWLRQRI$IULFDQ-
$PHULFDQV6RZKDWGR,GRQH[WWLPH",JRWR*HRUJLDRUSODFHVOLNHWKDWZKHUH,¶OOKDYH
more chances of getting some African-$PHULFDQV´µ3ODFHVOLNHWKDW¶WKDWLVSODFHVZRUVW
affected by enslavement and its contemporary legacies, have become attractive locations for 
drug companies seeking to increase their representation of ethnic and racial minorities. This 
demonstates the economic potential pharmaceutical companies locate in racialised and 
impoverished Americans, if not for the production of race-specific products, then at least for 
                                                          
 
2
 http://www.bridgeclinical.com/ 
3
 http://www.lanzargroup.com/count 
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ensuring the approval of pharmaceuticals for the general population by a regulatory body 
eager to redress existing discrepancies. Whilst, at first sight, pharmaceutiFDOFRPSDQLHV¶
strategies targeting the bodies and spaces most scarred by centuries of racism and its 
contemporary legacies appears to carry forward the long history of racial exploitation, we 
contend that the logics at play here cannot be fully captured by such lines of argumentation. 
We will provide a more comprehensive analysis after briefly considering the case of the UK 
public stem cell bank to draw out important analogies and differences.  
The Blood Stem Cell Inventory of the UK 
7KH8.¶VSXEOLFEORRGVWHPFHOOLQYHQWRU\FRPSULVHVERWKWKHQDWLRQ¶VERQHPDUURZ
registries and umbilical cord blood banks, and acts as a window through which UK-based 
transplant clinicians might locate stem cell tissue for patients requiring a blood stem cell 
transplant (Anthony Nolan 2015). This inventory operates partly through revenue from the 
state, but also on the sale of its stem cells to requesting health services. For example, in the 
UK an individual umbilical cord blood (UCB) unit might be sold for around £17,000 either to 
a UK NHS hospital or to a foreign hospital. Likewise, UK NHS hospitals might purchase 
units from abroad if they cannot find a suitable one in the UK (different inventories charge 
different amounts). Elsewhere, Williams (2015) has explored how these economic mediations 
are important in understanding why and how WKH8.¶VSXEOLFLQYHQWRU\LVWU\LQJWRGHYHORS
itself as a self-sufficient provider of stem cells that will eventually preclude foreign (and 
potentially expensive) import. 
Race plays an important role in these mediations. IWLVXQGHUVWRRGWKDWHDFKLQGLYLGXDO¶VFHOO
surfaces are composed of various proteins or alleles²our own tissue type. This is how our 
bodies determine which matter within us is our own, and which is potentially harmful and 
therefore in need of rejection (Erlich, 2012). Individual cell composition is directly related to 
RQH¶VSDUHQWDJHZKLFKLVZK\PRVWWUDQVSODQWVWDNHSODFHEHWZHHQUHODWHGLQGLYLGXDOVOLNH
siblings. When an appropriate related donor cannot be found for a patient however, clinicians 
can use resources like WKH8.¶VVWHPFHOOLQYHQWRU\ZKHUHDODUJHSRROof stem cells may be 
searched for tissue with cell surfaces as similar to the patient as possible (Brown and 
Williams, 2015). 
Scientific understandings of this process invoke an explicitly racialised register of language. 
As explained above, stem cell inventories rely on locating similarity between bodies that are 
not related. Through the development of immunological and population genetics research 
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through the 1960s and 1970s, it is now understood that particular allelic structures of cell 
surfaces (the basis of locating a suitable donor for oneself) are more frequent in certain 
µSRSXODWLRQV¶7KLVXQGHUVWDQGLQJhad a profound impact on early transplant science (Thomas, 
1994; Williams, 2017a), such that the notion of race often becomes interchangeable with 
genetic population in this scientific community; as with the pharmaceutical drug trial, 
categories of difference used in scientific and social practice are rendered equivalent, 
reinforcing socially salient categorisations through the assertion of biological facticity, which 
can be mobilised, as we will see, to encourage minority participation. 
Mirroring efforts to incorporate ethnic minorities into drug trials, there is an ongoing call to 
increase ethnic minority stem cell donation to the UK stem cell inventory. If a Black patient is 
indeed more likely to find a match from a Black donor, it matters that in the UK, the 
composition of the public stem cell inventory is saturated with self-identified white donors, 
but proportionally underrepresents non-white donors in relation to the UK population (see 
Anthony Nolan, 2015). Alongside this is the important issue of the NHS needing to avoid 
costlier interventions, like the importation of non-domestic stem cells. Ultimately, then, 
addressing what is seen as a dearth of Black donation stands to save more lives, and save 
money (Williams, 2015). This call has KDGVLJQLILFDQWXSWDNHZLWKWKH8.¶VVWHPFHOO
inventory having a mandate since 2010 to actively increase UCB donation and stem cell 
registrations amongst minorities.  
The effort to maximise acts of donation from minorities is, for example, instructive in where 
UCB is collected. As two individuals involved in the All-Party Parliamentary Group (APPG) 
on Stem Cell Transplantation described during interviews: 
³$SHWLWLRQZHQWRQLQ0DQFKHVWHUE\WKH03«WRKDYHDFROOHFWLRQVLWH
RSHQHGWKHUHDQGWKDW¶VZK\ZH¶YHHQGHGXSLQ0DQFKHVWHU$JDLQDQRWKHU
place with lots of babies and good diversity.´  
³«ZHFROOHFWDW.LQJ¶V«EHFDXVH.LQJ¶VKDVDKXJHQXPEHURIHWKQLF
PLQRULWLHV«<RXEDVLFDOO\WDUJHWWKHUHJLRQEHFDXVHWKDW¶VZKHUHWKHUHDUH
lots of mothers of ethnic minority groups.´  
In the first quote, the interviewee explains that a collection site in Manchester is a rational 
choice not only because of the density of births ± µORWVRIEDELHV¶± but also the high numbers 
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of ZRPHQFRPLQJIURPµHWKQLFPLQRULW\JURXSV¶(FKRLQJWKLVWKHVHFRQGTXRWHQRWHVWKDW
.LQJ¶V&ROOHJH+RVSLWDORQHRIWKH/RQGRQFROOHFWLRQVLWHVLVVLPLODUO\DWWUDFWLYH, with its 
catchment areas of Lambeth, Southwark and Lewisham, the three London boroughs with the 
highest density of Black residents, according to the 2011 census (Office for National 
Statistics, 2013). This focus on ethnic minority donors again reveals an acknowledgement of 
the perceived vital potential of their bodies, relatively rare as they are in comparison to white 
bodies. Such opportunities are thus seized to maximise opportunities for donation. This is 
perhaps most starkly evident in the account of another individual involved in the APPG. They 
described in an interview how there has been a: 
³IRFXVRQKRVSLWDOVZKLFKKDYe a high birth rate. Preferably a high birth rate 
RIGLYHUVHHWKQLFPRWKHUVDQGWKDW¶VZKDWZH¶UHIRFXVHGRQ6R0UV-RQHVRXW
in little Bollock-on-the-Wold going into her local maternity hospital? She 
GRHVQ¶WKDYHDFFHVVWRWKDW´  
The hypothetical Mrs Jones resides in the fictional Bollock-on-the-Wold (reminiscent of the 
similarly hyphenated rural Cotswolds town of Stow-on-the-Wold). Mrs Jones ± her whiteness 
inferred by one of the most common British surnames in the UK census (McElduff et al., 
2008) and a rural (and thus predominantly white) residence (Parkinson et al 2006) ± is not in 
WKHVFRSHRIµIRFXV¶,QVWHDGWKHIRFXVLVSODFHGRQ KRVSLWDOVZKHUHWKHUHDUHµGLYHUVHHWKQLF
PRWKHUV¶ Just like the multinational drug company explicitly focuses on Georgia to recruit 
African American research subjects, the UK stem cell inventory targets its donation in areas 
with more non-white people. Such a tacit acknowledgement of the precedence of non-white 
over white donors reveals how the vital potential of non-white bodies is recognised and 
tapped into through practical means.  
Discussion: the value of racialised communities 
The construction of rarity in minority ethnicity is rooted in a particular and deeply 
problematic history. Richard Titmuss, author of The Gift Relationship, was attuned to it, 
cautioniQJKLVUHDGHUVWRUHPHPEHUWKH³contemporary world-wide phenomena of racial 
SUHMXGLFHDQGLWVDVVRFLDWLRQZLWKFRQFHSWVRIEORRGLPSXULWLHVµJRRG¶EORRGDQGµEDG¶EORRG
untouchability DQGFRQWDPLQDWLRQ´ (1970: 20). However, as we have outlined earlier in the 
paper, we argue that our examples present almost an inversion of this logic. In both cases, the 
construction of rarity in racialised tissue stands to produce tangible economic benefits. In line 
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with the discovery of previously marginalised populations as sources for the creation of profit 
(Gilroy, 2013), the convergence of bioscientific interrogations of racial difference and market 
principles has conferred a certain value on race. But, in both cases, recruitment agencies and 
collection managers also attempt to combat the underrepresentation of minorities, focusing 
more intensely on those bodies previously excluded from biomedical attention and care.  
Both vignettes LOOXVWUDWHKRZELRVFLHQWLILFSUDFWLFHVGHSOR\UDFLDOLVHGPLQRULWLHV¶FROOHFWLYH
social identities, drawing heavily on an affective repertoire of community responsibility to 
engage racialised groups in acts of participation and donation. Pharmaceutical companies, 
CROs, and organisations involved with the stem cell inventory aim to remind trial participants 
and stem cell donors of their collectivised responsibility towards one another. They thereby 
reframe the obligation of their racialised audiences as an ethical self-fashioning to eliminate 
health inequalities. For example, both the ,¶PLQ campaign and stem cell collection registries 
deploy community outreach workers and advocates, sometimes themselves former 
SDUWLFLSDQWVRUVWHPFHOOUHFLSLHQWV¶IDPLO\PHPEHUVZKRH[SOLFLWO\XVHWKHLUUDFLDOLGHQWLW\WR
attract potential participant-donors. The ,¶PLQ website features testimonies of patients and 
SDUWLFLSDQWVVXFKDVWKHIROORZLQJE\DQXUVHSUDFWLWLRQHUZKRDUJXHVWKDWLQRUGHU³WRJHW
more people of color open and willing to participate, you have to have somebody who looks 
OLNHWKHP´6LPLODUO\WKHbone marrow patient activist cited above acknowledges a need for 
his organisation, which encourages Black stem cell donation, to adopt a particularly µBlack 
mode of communication¶³:H¶UHWDNLQJWKHJHQHULFPHVVDJH«DQGZHFRXFKLWLQD
frequency, in a way WKDWVXGGHQO\RXUSHRSOHUHFRJQLVHµQRZ,KHDU\RX¶´,QERWKFDVHVWKH
GHOLQHDWLRQRIµRXUSHRSOH¶RURISHRSOHµZKRORRNOLNHWKHP¶ highlights how what Rogers 
%UXEDNHUWHUPV³HWKQRSROLWLFDOHQWUHSUHQHXUV´VSHFLDOLVWVZKROLYHµRII¶DVZHOl 
DVµIRU¶UDFHRUHWKQLFLW\ZRUNWRDWWUDFWSDUWLFLSDQWVRUGRQRUVWKURXJKDIIHFWLYHO\LQYRNLQJD
mutual objective qua shared racial identification.  
Both projects foster a moral appeal to community that looks to create an active sense of 
solidarity with a community of suffering that has long been the subject of both biological 
damage and biomedical neglect (Inda, 2014; Nelson, 2012). Towards the end of the ,¶PLQ 
UHFUXLWPHQWYLGHRIRULQVWDQFHWKHXQVHHQQDUUDWRUHPSKDWLFDOO\DSSHDOVWRWKHYLHZHU¶VVHQVH
of responsibility for their own health and ± crucially that of the identities actors and 
FRQVXPHUVSUHVXPDEO\VKDUH³,W¶VQRWHQRXJKWRZDLWIRUVRPHRQHHOVHto act. We all have a 
UROHWRSOD\:HDOOKDYHDUHVSRQVLELOLW\WRHDFKRWKHUDQGIXWXUHJHQHUDWLRQV´KHGHFODUHV
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The campaign centrally draws on the neglected or wounded body as a powerful metaphor 
around which ethnic and racial minorities have historically organised (Nelson 2012), directly 
appealing to a sense of common responsibility. This point is also present in the case of public 
stem cell provision. Discussing blood donation systems nearly fifty years ago, Titmuss 
UHFRJQLVHGWKHSRVVLELOLW\³WKDW EHFDXVHRQH¶VEORRGLVUDUHRUXQLTXH´DQLQGLYLGXDOPLJKWEH
PDGHWRIHHOD³SDUWLFXODUUHVSRQVLELOLW\WRPDNHLWDYDLODEOHWRRWKHUVZKRPD\QHHGLW´
(1970: 263). Although Titmuss was discussing blood rather than stem cell donation, the point 
is echoed in a quote from an individual involved in an organisation that encourages ethnic 
minority stem cell donation. 
«ZHDUHWKHYDQJXDUGRIWKLVPRYHPHQWRIJHWWLQJHWKQLFPLQRULWLHV
especially Black and mixed raced people to realise: take your health 
seriously, especially when it comes to cancers and especially when it relates 
directly to race. You need to be ready to try and help someone else because 
\RXQHYHUNQRZZKHQ\RXPLJKWQHHGLW\RXUVHOI«7KDW¶VDYHU\
VSHFLDOLVHGPHVVDJHWKDW¶VJRWWREH«FRXFKHG in a way that will resonate 
with families and mothers-to-be when they hear it.  
The militaristic inference RIDµYDQJXDUG¶ is suggestive of being on the frontline of a battle in 
bringing ethnic minorities to a realisation of the sharedness of their community and the 
mutuality of their responsibility toward one another. The participant puts this quite bluntly, 
VWDWLQJWKDWRQHPXVWEHµUHDG\WRWU\DQGKHOSVRPHRQHHOVHEHFDXVH\RXQHYHUNQRZZKHQ
\RXPLJKWQHHGLW\RXUVHOI¶GUDZLQJRQWKHVDPHWRQHRIREOigated reciprocity that 
underwrites the ,¶PLQ video campaign explored above. This obligation to others in the group 
PXVWEHµFRXFKHG¶VRWKDWLWZLOOµUHVRQDWH¶ZLWKWKHSRWHQWLDOGRQRUV7KLVDIIHFWLYHUHVRQDQFH
is a central element in the augmentation of donation. Awareness raising is therefore not 
simply about highlighting the illness and the statistical probabilities of locating a match, but 
RIKLJKOLJKWLQJSRWHQWLDOGRQRUV¶UHVSRQVLELOLWLHVWRWKHir community. 
In this sense, the reinforcement of biological affiliation and mutual responsibility serves to 
mobilise participating individuals to themselves encourage participation from others. 
3DUWLFLSDQWWHVWHPRQLDOVDQGSDWLHQWDFWLYLVWVPLJKWWKXVEHUHDGDVHYLGHQFHRILQGLYLGXDOV¶
recognition of their own subjectivity. The techniques and languages deployed in our examples 
QRWRQO\VKDSHSDUWLFLSDQWV¶VHOI-understandings vis-à-YLVµWKHLU¶UDFLDOLVHGFRPPXQLWLHVEXW
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also activate their sense of responsibility for their fellow group members, while at the same 
time distinguishing themselves from other, non-group members predominantly in somatic 
terms. As such, this collective self-governance resonates with what Rose has termed projects 
of biological citizenship in which  ³ELRORJLFDOVHQVHVRILGHQWLILFDWLRQ and affiliation made 
FHUWDLQNLQGVRIHWKLFDOGHPDQGVSRVVLEOHGHPDQGVRQRQHVHOIRQRQHV¶NLQFRPPXQLW\
VRFLHW\´ (Rose, 2006: 133). Within this normative ethical framework, it is possible to 
participate and be a good biological citizen, or refrain and be a bad one. This logic also plays 
out in Ruha Benjamin¶V(2013) analysis of African American sickle cell disease activism in 
WKH867KHFRPPXQLW\RIDSRWHQWLDOLOOQHVVVLFNOHFHOOLVFDVWXQTXHVWLRQLQJO\DVDµ%ODFN¶
disease) is a powerful tool to mobilise action ± and to castigate inaction. Just as there can be 
good and bad biological citizens, the refusal to express solidarity in the pursuit of a cure for 
sickle cell amounts, as Benjamin highlights, WRDNLQGRIµFLYLFGHIHFWLRQ¶Amongst Black 
donors and recipients, or participants and future consumers, made into a community because 
of the allusion to their cellular compatibility, to not participate is anathema. Likewise, in our 
own examples, minoritised peoples are compelled to engage in helping to improve or even 
save the lives of others in their communities qua their historical relationship through shared 
suffering.  
Despite their progressive intentions, we find these appellations to a particularly racialised 
obligation to participate or donate to be highly problematic. They affirm the legitimacy of 
groupings based on biological understandings of race, breaking with the trend towards 
personalised treatment based on the calculation of individual risk factors. As other critics have 
warned, deploying race-based markers in the µmeantime¶ EHWZHHQWRGD\¶VRQH-size-fits-all 
model and tomorrow¶s practice of personalised medicine risks reconfiguring race from a 
rather crude proxy for genetic variation to an increasingly viable, and widely used, 
placeholder (Kahn, 2012). At the same time, the practices in our examples also appear to 
LQFHQWLYLVHUHVSRQVLELOLW\RQO\ZLWKLQRQH¶VUDFLDOJURXSUDFLDOLVLQJWKHUHVSRQVLELOLW\WR
GRQDWHLWVHOI6XFKDWWHPSWVDPSOLI\DV.LHUDQVDQG&RRSHUQRWH³WKHLGHDWKDW
donation is the collective responsibility of biologically, socially and culturally distinct and 
GLVWLQJXLVKDEOHFRPPXQLWLHV´As projects of biological citizenship, they not only proclaim 
membership to particular biological groups but also demarcate non-membership. Consider, 
for example, this excerpt from a media interview with campaign co-founder and NMQF CEO 
*DU\$3XFNUHLQ³,ISHRSOHZKRGRQ
WORRNOLNH\RXDUHQ
WLQFOLQLFDOWULDOV´KHQRWHV³ZKHQ
WKHWLPHFRPHVZH¶OOEHSOD\LQJ5XVVLDQURXOHWWHZLWK\RXUKHDOWKEHFDXVHZHGRQ¶WKDYHWKH
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VFLHQFH´&Rlliver, 2014, emphasis added). Illustrating not only the superimposition of 
identity politics and genetic variation, Puckrein also suggests it is only people who share 
phenotypic representations that can exercise care towards, or stand in a reciprocal 
relationships of responsibility ZLWKHDFKRWKHU3DWLHQWVZKRGRQRWµORRNOLNH¶WKDWLVUDFLDOO\
identify with the minorities portrayed in the video, are exempted from their responsibility to 
enrol themselves in clinical trials for the next generation of patients-to-be. This suggests a 
SDUWLFXODUUDFLDOLVHGGLPHQVLRQRIWKH³UHVSRQVLELOL]DWLRQ´RIDQGWKURXJKQHROLEHUDOPDUNHWV
(Shamir, 2008).  
The centrality of particular groups also speaks to how in neoliberalism, the discourse of 
community directly feeds into the operations of capitalism. Writing against µthe romance of 
FRPPXQLW\¶Miranda Joseph argues that the modern creation of identity-based communities 
directly benefits capitalist production. The ³LQGHWHUPLQDWHQHVVRIFDSLWDO´VKHZULWHV ³its 
openness to determination by use-YDOXHLVDQRSHQLQJWRµFRPPXQLW\¶WRGHWHUPLQDWLRQE\
VRFLDOUHODWLRQVDQGµYDOXHV¶LQH[FKDQJHSURGXFWLRQDQGFRQVXPSWLRQ´7KH
neoliberal utilisation of diversity, for her, is a direct outcome of this discourse of community 
that today is no longer centred on a specific national but on various social identities. The 
production of economic value is predicated on the production and consumption of 
community, and often particular racialised communities, as we aimed to illustrate through our 
empirical examples. In both our vignettes the narrative of community responsibility functions 
as a regime through which racialised communities are invoked for the creation of new 
markets in human tissue. These communities are thereby actively (re)produced as racial 
through the somatic connections established by the scientific reification of racial categories. 
While immediate commercial incentives can be more clearly located in the case of clinical 
drug trials, public stem cell banking initiatives, as Nik Brown (2013) notes, also take on 
substantial symbolical and economic attributes in their constitution as systems of exchange 
value ± not least because these stem cells are bought and sold potentially internationally by 
public and private health providers for their patients (Williams, 2017b)  
The highly affective efforts to cultivate attachment between the participant-donor and their 
obligation to a particular racialised community exemplify the ways in which the creation of 
such communities is central to the creation of value, in the double sense of tangible profits to 
be derived and the social values to be realised. The potential economic surplus (we emphasise 
potential as both pharmaceutical development and stem cell banking are highly speculative 
18 
 
 
practices in that they could well never lead to a new drug or an actual tissue transplant) cannot 
be disentangled from the social values of accessibility of care, amelioration of health 
inequalities and improving quality of life. The generation of economic value in health markets 
is always also tied to the cultivation of vitality and well-being (Rose, 2006; Inda, 2014; 
Waldby, 2002). In other words, despite their racialising functions, we locate both stem cell 
banking and drug trials at the life-affirming pole of twenty-first century biopolitics (Rose, 
2006; Rabinow and Rose, 2006). Though they are firmly embedded in market frameworks 
and the pursuit of profits, the vital politics exposed in our examples also aim at nurturing and 
extending rather than limiting life at the genomic level.  
Through the scientific work of locating racial or ethnic, read, JHQHWLFµSRSXODWLRQV¶ZKRPLJKW
find their tissue match from another within that population, we simultaneously witness the 
assembling of a public with all its ³symbolic and discursive appeal´ (Hinterberger 2012: 530). 
This invocation of a public has more than one purpose. The ,¶PLQ campaign seeks to engage 
participants in a project that could produce new pharmaceuticals and thus profit for private 
drug companies. But the engagement, often fuelled by political incentives, also has the 
purpose of maybe saving the lives of some individuals in the community the participant is 
reaffirmed as existing within. Likewise, the public animated in the stem cell case is engaged 
specifically with the purpose of participating in a medical effort to save lives of patients 
needing transplants. Implicit in this is the requirement of a struggling health service to ensure 
the treatments that are commissioned are affordable. A domestic stem cell unit is likely to be 
much cheaper than an imported one, and mobilising a public seeks to make the domestic stem 
cell inventory more able to serve UK clinical requirements. 
This highlights, for us, how these different tenors of value, economic and ethical, are co-
constituted. The profits portended by drug development, and the savings anticipated by 
domestic stem cell provision, cannot be understood without the more ethical framing of value 
as the capacity for these drugs and stem cells to become lifesaving medical interventions, 
particularly for racially marginalised bodies and groups. In the life sciences, value itself does 
not only imply material valuation by the market but also suggests a genuine concern with the 
meanings and practices of ethics (Rajan, 2006). Far from obfuscating the bare economics of 
exchange that contemporary bioscience entails (Birch and Tyfield, 2012), we argue that the 
intangible mobilisation of UHVSRQVLELOLW\WRZDUGVRQH¶VFRPPXQLW\ and the evocation of an 
ethical self-fashioning sit at the epicentre of value production vis-à-vis racialised biological 
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difference. The value produced here FDQQRWEHYLHZHGSXUHO\WKURXJKWKHOHQVRIOLIH¶V
commodification, but also its improvement and extension. 
Of course, though, such goals as the improvement and extension of life are important to 
scrutinise. This is particularly so in the two contexts we have analysed in this paper. In the 
US, the Affordable Healthcare Act hangs perilously in the balance, with the mooted 
replacement legislation ready to increase the number of those without basic health coverage  
E\VRPHPLOOLRQ&RQJUHVVLRQDO%XGJHW2IILFH7KH8.¶V National Health Service, 
beset by political GHPDQGVWREHFRPHPRUHµVXVWDLQDEOH¶ in the context of a slowing rate of 
JURZWKLQLWVIXQGLQJ.LQJ¶V)XQGD, is regularly described as in crisis, with increased 
waits for treatments .LQJ¶V)XQGE It is in the shadow of this state of affairs that 
%HQMDPLQ¶VZRUGVDERXWLQYHVWPents in biological research are insightful. One can sense, she 
aptly VXJJHVWVDµVRFLDOGLVVRQDQFH¶LQLQYHVWLQJPRQH\LQH[SHULPHQWDOUHVHDUFKZHPLJKW
also extend this to relatively rare treatment protocols like stem cell transplantation) when so 
many in the US (and we might extend this to the UK) struggle to access more basic forms of 
healthcare. The focus on rarer treatments and speculative research is ³comparable to sweeping 
XSEURNHQJODVVZKLOHWKHPRUHSUHVVLQJIODPHV«DUHOHIWWRZUHDNKDYRF´ (Benjamin, 2013: 
124). 
Conclusion   
Examining two different bioscientific contexts, US clinical drug trials and UK public stem 
cell donation, in this paper we have suggested that racial difference stands to be highly 
valuable in the neoliberal bioeconomy. We have argued that this value cannot be purely 
understood as the commodification of racial lives though; rather, analyses need to be attentive 
to the social, medical and ethical registers enmeshed in value production. We have shown 
how the mobilisation of a discourse of mutual obligation within racialised communities, itself 
both tied to economic and moral imaginaries, functions as a central theme in attaching the 
participant-donor to a particular racialised community. Our analysis suggests that it is wise 
QRWWRFDSLWXODWHWRWKHODEHOµFRPPRGLILFDWLRQ¶LQWKLVVFHQDULR; though the term is befitting of 
those cases where an unabashed profit motive reveals itself, for the cases we have examined it 
ZRXOGEHDQDO\WLFDOO\UHPLVVWRGLVHQWDQJOHWKHSURMHFWV¶FDSDFLWLHVIRUthe derivation of 
capital from the health benefits that their strategic successes as private and public initiatives 
might unlock.  
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However, we suggest it is necessary, in the contemporary political moment, to critically 
interrogate a system that valorises the communities of Black folks while still firmly 
prioritising white folks in most other areas of life. As the case of BiDil, the ILUVWµUDFH-
VSHFLILF¶drug, has made ironically clear, products or services targeted at historically 
disenfranchised groups may well fail to reach their markets because these groups cannot 
afford to buy them (Pollock, 2012). More destructive still, such efforts can quite easily 
distract from the larger, structural issues that condition the very racial inequalities and 
underrepresentation to which these solutions respond. The logic of fostering racial vitality 
through pharmaceuticals or other biotechnologies is not so obviously at work outside the 
clinic or lab where potentially profitable products may be derived. Again, Benjamin 
highlights this deep asymmetry between scientific and political life today, arguing that ³our 
investment of both time and money in reengineering biological life far exceeds our collective 
will to transform social life´ (2013: 176). The rise of the Black Lives Matter movement 
illustrates that establishing more equitable social conditions requires much more ± of all of us 
± than participation in clinical trials and tissue donation. Analyses of how race is put to work 
for the production of value in biomedicine must be attuned to this political and social reality. 
Racialised bodies do matter in the lab and the clinic; beyond this domain, however, the value 
of these same bodies remains firmly in question.  
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